Here's the naive question: what does a company actually mean when it says it has a vaccine franchise? In Moderna's case the answer is unusually concrete, because the company defines it in its annual report. A franchise, here, is a family of products aimed at the same broad problem and built on the same underlying technology.
The 2026 annual report (10-K, filed February 20, 2026) lists three commercial respiratory vaccines: Spikevax and mNEXSPIKE, which are COVID vaccines, and mRESVIA, an RSV vaccine. Think of it like a product line at a company — same factory, same engine, different models aimed at different customers. The shared engine here is mRNA, the instructions-not-ingredients approach that lets one manufacturing platform make many different vaccines.
Why group them as respiratory? Because the diseases share a season and an audience. COVID, RSV, and influenza all surge in the colder months and all threaten the same vulnerable groups. Moderna's filings going back years describe an ambition to build a broad seasonal respiratory vaccine franchise consisting of single-agent, next-generation, and combination vaccines — the company's own framing of a one-stop seasonal shot.
The combination idea is the strategic payoff. If you can make a COVID vaccine and an RSV vaccine and a flu vaccine on the same platform, you can in principle combine them into a single annual injection — the way the flu shot already bundles multiple strains. That is the long game the franchise language points at: fewer needles, one platform, recurring seasonal demand.
The short version of the business logic: a franchise turns a one-time pandemic product into a repeatable seasonal business. Spikevax was born in the COVID emergency; mNEXSPIKE and mRESVIA are the company trying to convert that platform into something that sells every autumn, the way flu shots do, rather than something that depended on a once-in-a-century event.
The EdgarBeast evidence index lets a reader pull the franchise definition straight from Moderna's filings rather than from marketing copy — and the filings are refreshingly literal about it. A respiratory vaccine franchise, in Moderna's own words, is three mRNA vaccines today and a combination ambition for tomorrow.